TOBI®: PROVEN TO REDUCE HOSPITAL DAYS1,2

TOBI demonstrated a significant reduction in hospital days
for CF patients with Pa1


In pivotal studies, TOBI patients spent an average of 5.1 days in the hospital over 24 weeks compared with an average of 8.1 days for those patients taking placebo.2

37% fewer days in hospital

Results from 2 identical, randomized, multicenter, double-blind, placebo-controlled trials. Patients were treated with 300 mg of aerosolized tobramycin (n=258) or placebo (n=262) twice daily in 3 cycles, with each cycle consisting of 28 days during which the drug was administered and 28 days during which the drug was not administered. The primary efficacy end point was change in FEV1 at week 20.1,2

In pivotal studies with TOBI, patients treated with TOBI were 26% less likely to be admitted to the hospital compared with placebo (95% CI, 2%-43%).1

 



Important Safety Information full Prescribing Information www.fda.gov/medwatch

References:

  • Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. N Engl J Med. 1999;340:23-30.
  • TOBI [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2009.